{"groups":[{"description":"Participants received 4 capsules of ibrutinib-matching Placebo administered orally once daily continuously starting on Day 1, Cycle 1 until disease progression, or unacceptable toxicity, or study end, whichever occurred first. All participants also received a maximum of 6 cycles of BR background therapy (bendamustine hydrochloride 90 milligrams per meter square \\[mg/m\\^2\\] intravenous \\[IV\\] infusion on Days 1 and 2 of each cycle and rituximab 375 mg/m\\^2 IV infusion on Day 1 of each cycle), unless disease progression or unacceptable toxicity prior to Cycle 6. Participants with a complete response (CR) or partial response (PR) continued to receive background therapy with rituximab maintenance (375 mg/m\\^2 IV infusion) on Day 1 every second cycle starting at Cycle 8 for a maximum of 12 additional doses unless disease progression or unacceptable toxicity. Each cycle was of 28 days. Participants received treatment A up to 100.1 months. After treatment unblinding at the time of the primary analysis, participants randomized to Treatment A discontinued placebo treatment.","id":"FG000","title":"Placebo + Bendamustine and Rituximab (BR) (Treatment A)"},{"description":"Participants received ibrutinib capsules 560 mg (4\\*140 mg capsule) administered orally once daily continuously starting on Day 1, Cycle 1 until disease progression, or unacceptable toxicity, or study end, whichever occurred first. All participants also received a maximum of 6 cycles of BR background therapy (bendamustine hydrochloride 90 mg/m\\^2 IV infusion on Days 1 and 2 of each cycle and rituximab 375 mg/m\\^2 IV infusion on Day 1 of each cycle), unless disease progression or unacceptable toxicity prior to Cycle 6. Participants with a CR or PR continued to receive background therapy with rituximab maintenance (375 mg/m\\^2 IV infusion) on Day 1 every second cycle starting at Cycle 8 for a maximum of 12 additional doses unless disease progression or unacceptable toxicity. Each cycle was of 28 days. Participants received treatment B up to 117.2 months. After treatment unblinding at the time of the primary analysis, participants randomized to Treatment B continued treatment with ibrutinib at the discretion of the investigator.","id":"FG001","title":"Ibrutinib + Bendamustine and Rituximab (BR) (Treatment B)"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"12"},{"groupId":"FG001","numSubjects":"7"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"32"},{"groupId":"FG001","numSubjects":"48"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"89"},{"groupId":"FG001","numSubjects":"87"}],"type":"Sponsor decision"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"262"},{"groupId":"FG001","numSubjects":"261"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"260"},{"groupId":"FG001","numSubjects":"259"}],"type":"Safety Analysis Set (Treated)"},{"achievements":[{"groupId":"FG000","numSubjects":"129"},{"groupId":"FG001","numSubjects":"119"}],"comment":"Participants who died were considered to have completed the study.","type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"133"},{"groupId":"FG001","numSubjects":"142"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"A total of 523 subjects were randomized in this study."}